This morning Senseonics, an implantable glucose sensor company, announced that data from its Eversense continuous glucose monitor will be integrated into the Glooko diabetes management platform. This ...

Senseonics Holdings, Inc. SENS recently scored a meaningful regulatory win in Europe, receiving CE Mark approval for its ...

Eversense 365 is the world’s first and only one year CGM, which was approved by the United States (US) Food and Drug Administration in September of 2024 and launched across the country in October of ...

On Friday, Senseonics, maker of the implantable continuous glucose monitoring system Eversense, announced a new program geared towards patients with high-deductible insurance plans or plans that don’t ...

PARSIPPANY, N.J., April 24, 2023 /PRNewswire/ -- Ascensia Diabetes Care, a global diabetes care company, maker of the CONTOUR ® Blood Glucose Monitoring (BGM) system portfolio and exclusive ...

The decision is further recognition of Eversense as an important option for people with diabetes PARSIPPANY, N.J., Feb. 12, 2024 /PRNewswire/ -- Ascensia Diabetes Care, a global diabetes care company, ...

GERMANTOWN, Md., Feb. 06, 2025 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NYSE American: SENS) a medical technology company focused on the development and manufacturing of long-term, implantable ...

Detailed price information for Senseonics Holdings Inc (SENS-Q) from The Globe and Mail including charting and trades.

Sequel Med Tech and Senseonics have announced a collaboration to integrate Sequel’s twiist Automated Insulin Delivery (AID) System with Senseonics’ Eversense 365 one-year Continuous Glucose Monitoring ...

GERMANTOWN, Md., Jan. 29, 2026 (GLOBE NEWSWIRE) -- (NASDAQ: SENS) a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CG ...